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abstract
An overview of life expectancy in Malta over the past sixty 
years shows a remarkable increase for both men and women. 
However, gains in life expectancy were not constant throughout 
the period. The rate of increase as well as the attributable causes 
of the noted increase varied over the years. Disparities in life 
expectancy by gender and by level of education exist. Life 
expectancy in Malta has caught up with Western Europe over 
the past 30 years and now compares well with the average for 
the EU-15. (The EU-15 consists of the 15 EU member states who 
became members in the European Union before 2004 and on 
average have the best life expectancies in the EU).  
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IntroductIon
The extension of the human lifespan has been significant in 
recent years, with world average life expectancy at birth having 
more than doubled over the past two centuries1 and rising 
by more than one-third in just the last four decades.2  Life 
expectancy is often used by countries as a measure of population 
health. It is an indicator that summarizes the mortality 
conditions in a country in a given year. Life expectancy at birth 
shows the number of years that a person can expect to live if 
current mortality conditions would prevail in the future.
The world average life expectancy for males stood at 69 years 
for males and 73 years for females in 20153 with highest average 
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Figure 1. Life expectancy at birth in 2014 by Broad World Regions.4
Figure 2. Trends in life expectancy in males and females in Malta
life expectancies by broad regions being attained in Europe and 
North America (Figure 1).4 In sharp contrast, life expectancy 
gains have been modest in Africa. In fact, due to the impact 
of AIDS, during the 1990s life expectancy actually decreased; 
however, since 2005 mortality due to HIV/AIDS has been 
decreasing, allowing life expectancy at birth to increase again.5
The original “epidemiological transition” theory by Abdel 
Omran6 was the first attempt to explain the progress in 
healthcare made by industrialised countries over the past two 
centuries. Further refinements of the original theory were made 
and are described as the stages of the ‘health transition’.7 Between 
the turn of the 18th century and the 1960s, life expectancy 
improved dramatically from low levels of 30-35 years to reach 
about 70 years in the mid-1960s. This was primarily due to the 
reduction in mortality from infectious diseases. Improvements 
in living conditions, wealth and nutrition together with 
important public health measures including investment in safe 
drinking water and sewage systems were important measures 
responsible for major reductions in mortality from infectious 
diseases. This was followed by the introduction of immunisation 
and antibiotics. Since the 1970’s, we are experiencing a second 
stage in health transition relating to the reduction of cardio-
vascular disease, at least in high-income countries. More 
recently, some countries are now experiencing a third stage 
(possibly without having completed the previous one), which 
is the fight against ageing. However, these stages may occur at 
different times in different countries.7  
In Malta … It Is of note that the Gender Gap observed wIth lIfe 
eXpectancy dIsappears when consIderInG healthy lIfe eXpectancy, 
IndIcatInG that the addItIonal lIfe eXpectancy In feMales tend to 
be lIved wIth decreased health and wIth actIvIty lIMItatIons
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the sItuatIon In Malta
An overview of life expectancy in Malta over the past 60 years 
has shown a steady increase (Figure 2), with life expectancy in 
2014 reaching 79.97 for men and 84.37 for women.8 However, 
it is well known that substantial disparities in average life 
expectancy exist and these are associated with socio-economic 
variables. Persons who have higher levels of education have a 
higher life expectancy at birth compared to those with lower 
education levels. This gap is wider for men than women i.e. 
Males: least educated 77.30, most educated 81.80; Females: least 
educated 82.40, most educated 84.10, in 2011.9
Over the past 60 years, gains in life expectancy varied from 
one decade to another. Detailed demographic analysis of gains 
between 1955 and 1980 reveal that the gains are attributable 
mainly to a fall in infant mortality, as seen in figure 3. During 
this period, life expectancy in the older age groups actually 
deteriorated resulting in an overall picture of life expectancy 
stagnation in the 1970s. The largest gains in life expectancy were 
experienced during the 1980s with more modest gains being 
made in the 1990s. These gains are mainly observed in the older 
age groups and are largely attributed to the start of a downward 
trend in circulatory mortality (Figure 4). 
Figure 3. Gains in life expectancy in Malta by period, age and gender
Figure 4. Trends in standardised mortality rate from circulatory diseases 
in Malta in males and females.8 SDR: Standardised Death Rate,  
M: Male, F: Female, MT: Malta.
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how does Malta’s lIfe eXpectancy trajectory coMpare 
to the eu-15?
According to the data for 2014, the life expectancy for men 
(79.97) and women (84.37) in Malta compares well with that 
of EU-15 (life expectancy for EU-15 stood at 79.06 for males 
and 84.23 for females); however, this has not always been the 
case. Figure 5 shows how life expectancy for women in Malta 
has been persistently lower than that of EU-15 and only seems 
to catch up now. In men life expectancy improvement lagged 
behind in the 1970s but caught up in the latter half of the 1980s 
and has largely remained similar to the EU-15 since then. 
A gender gap of around 4.5 years in life expectancy exists 
between men and women in Malta. This gap has remained 
relatively stable over the past 40 years. The gender gap in 
life expectancy varies substantially between different EU-28 
member states with large differences between the sexes found in 
Lithuania (11.1 years in 2013), and smaller differences found in 
the Netherlands, United Kingdom and Sweden (3.7, 3.7 and 3.6 
respectively).10
 
dIscussIon and conclusIons
This article has described the evolution of life expectancy in 
Malta over the past sixty years. It has highlighted the gender 
differences as well as the periods that have contributed greatest 
to the gains to life expectancy.
Contributions to gains in life expectancy reach far 
beyond the health sphere alone. While recent advances in life 
expectancy, at least in high-income countries, were largely due 
to declines in mortality from circulatory disease, this appears 
to be dependent on their economic growth. Transmission of 
knowledge and technology for the control of circulatory diseases 
from higher to lower income countries in Europe does not 
suffice and the answer may lie in developing stronger and more 
equitable economic conditions.13 
Gains in life expectancy in high income countries are 
resulting in an increase in the old age dependency ratio. In 
these countries ‘expected lifetime labour force participation as 
a percentage of life expectancy is declining’.14 As studies suggest 
that life expectancy will continue to increase in the years to 
come,15,16 countries facing such increase in longevity need to 
develop policies which will allow sustainable public pension and 
health care plans.  
Notwithstanding this, not all countries have the same aging 
pattern, and migration of workers from younger, often poorer 
countries, to older, often richer countries, may serve to balance 
the global distribution of labour and capital.2   
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Figure 5. Trends in life expectancy at birth in males and females in Malta 
compared to EU 15.9 LE: Life expectancy. 
eXtreMe lonGevIty for More people
The current data for Malta shows that the oldest recorded 
female death occurred at 109 years and the oldest male death 
occurred at 106 years. In the 1950s, deaths in the 85 plus age 
group accounted for 5% in men and 8% in women. In 2014 
they accounted for 23% and 43% of all deaths respectively.11 
Moreover, the old age dependency ratio (represents the number 
of people aged 65 years and over per workers aged 15-64 years) 
increased from 12% and 13% in males and females respectively 
in 1955 to 23% and 31% in 2014. Whether extra years of life 
gained through increased longevity are spent in good or bad 
health is a crucial question. In this context indicators of health 
such as healthy life expectancy (HLE) are of increasing interest. 
HLE is defined as the number of years that a person is expected 
to continue to live in a healthy condition (in absence of diseases 
or disabilities). In 2013, the HLE at age 65 was estimated at 
12.7 years for females and 12.8 for males in Malta, well above 
the EU-28 average (8.6, 8.5 respectively).12 It is of note that the 
gender gap observed with life expectancy disappears when 
considering HLE, indicating that the additional life expectancy 
in females tend to be lived with decreased health and with 
activity limitations.
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